Clinical trial
Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement
NCT03531294 is registered in ClinicalTrials.gov with Greater Houston Retina Research as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement
- Lead sponsor
- Greater Houston Retina Research
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 23, 2018
- Completion date
- April 9, 2021
- Enrollment
- 40 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.